Diabetes patients have long relied on complex glucagon kits to treat hypoglycemia. Late last summer, Xeris Pharmaceuticals aimed to change that with the first FDA-approved prefilled syringe. Now, its ...

Diabetes drugmaker Xeris Pharmaceuticals made a $75 million bet last summer when it went public to back an FDA submission for its shelf-stable glucagon injector pen. Now, more than a year later, Xeris ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying ...

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...

CHICAGO & DUBLIN--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ...

(RTTNews) - The U.S. Food and Drug Administration approved Eli Lilly and Co.'s (LLY) Mounjaro or tirzepatide injection for the treatment of adults with type 2 diabetes. Mounjaro represents the first ...

Asia-Pacific is emerging as the fastest-growing region. The global prefilled auto-injectors market is projected to grow at a CAGR of 8.4% from 2026 to 2033, rising from $5.6b in 2024 to $11.2b by 2033 ...